Loading market dashboard
Ventyx Biosciences, Inc.
VTYXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
LOS ANGELES, April 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ventyx Biosciences, Inc., (“Ventyx" or the "Company") (NASDAQ: VTYX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F.
JPMorgan Chase and Co. lifted its position in Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 748,088 shares of the company's stock after acquiring an additional 290,169 shares during the period. JPMorgan Chase
